Skip to main navigation Skip to search Skip to main content

Plasma-Activated Hydrogel Synergies With Paclitaxel to Enhance the Anticancer Efficacy

  • Zewei Wang
  • , Xixi Jing
  • , Zijin Wu
  • , Shengduo Xu
  • , Tong Wu
  • , Shiyao Wang
  • , Jishen Zhang
  • , Zifeng Wang
  • , Dingxin Liu
  • , Hao Zhang
  • , Mingzhe Rong
  • Xi'an Jiaotong University

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Cold atmospheric plasma-activated hydrogel (PAH) exhibits excellent loading and slow-release capacity for plasma-generated reactive species. In this study, plasma-activated pluronic F127 hydrogel (PAH-PF127) was obtained using surface dielectric barrier discharge (SDBD), and the anticancer effects of PAH-F127 synergies with the clinical drug paclitaxel (PTX) were investigated. The results indicated that PAH-PF127 could load plasma-generated long-lived reactive species efficiently, and in vitro research revealed that PAH-PF127 exerts significant anticancer effects by inducing intracellular oxidative stress, and synergies with 50 μg/mL (low-dose) PTX could easily replace 200 μg/mL (high-dose) PTX alone. These results suggested that PAH-PF127 has the potential to address the toxic side effects of high-dose drugs and expand the application of plasma technology in anticancer treatment.

Original languageEnglish
Article number2400167
JournalPlasma Processes and Polymers
Volume22
Issue number2
DOIs
StatePublished - Feb 2025

Keywords

  • anticancer effect
  • cold atmospheric plasma
  • plasma-activated hydrogel
  • reactive oxygen and nitrogen species

Fingerprint

Dive into the research topics of 'Plasma-Activated Hydrogel Synergies With Paclitaxel to Enhance the Anticancer Efficacy'. Together they form a unique fingerprint.

Cite this